Atrial fibrillation: comorbidities, lifestyle, and patient factors
- PMID: 38362547
- PMCID: PMC10866737
- DOI: 10.1016/j.lanepe.2023.100784
Atrial fibrillation: comorbidities, lifestyle, and patient factors
Abstract
Modern anticoagulation therapy has dramatically reduced the risk of stroke and systemic thromboembolism in people with atrial fibrillation (AF). However, AF still impairs quality of life, increases the risk of stroke and heart failure, and is linked to cognitive impairment. There is also a recognition of the residual risk of thromboembolic complications despite anticoagulation. Hence, AF management is evolving towards a more comprehensive understanding of risk factors predisposing to the development of this arrhythmia, its' complications and interventions to mitigate the risk. This review summarises the recent advances in understanding of risk factors for incident AF and managing these risk factors. It includes a discussion of lifestyle, somatic, psychological, and socioeconomic risk factors. The available data call for a practice shift towards a more individualised approach considering an increasingly broader range of health and patient factors contributing to AF-related health burden. The review highlights the needs of people living with co-morbidities (especially with multimorbidity), polypharmacy and the role of the changing population demographics affecting the European region and globally.
Keywords: Atrial fibrillation; Comorbidities; Lifestyle; Risk factors.
© 2023 The Author(s).
Conflict of interest statement
ES: none; EKC: Research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co., Daiichi-Sankyo, DeepQure, Dreamtech Co., Ltd., Jeil Pharmaceutical Co. Ltd., Medtronic, Samjinpharm, Seers Technology, and Skylabs; DAL: DAL has received investigator-initiated educational grants from Bristol Myers Squibb (BMS) and Pfizer; been a speaker for Boehringer Ingelheim, BMS/Pfizer and Bayer, and consulted for Boehringer Ingelheim and BMS/Pfizer; all outside the submitted work. DAL is also a co-applicant on EU Commission funded projects on atrial fibrillation; BJ: none; GYL: reports consultancy and speaker fees from BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo outside the submitted work. No fees received personally.
Figures
References
-
- Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. - PubMed
-
- Faselis C., Kokkinos P., Tsimploulis A., et al. Exercise capacity and atrial fibrillation risk in veterans: a cohort study. Mayo Clin Proc. 2016;91(5):558–566. - PubMed
-
- Kato M., Kubo A., Nihei F., Ogano M., Takagi H. Effects of exercise training on exercise capacity, cardiac function, BMI, and quality of life in patients with atrial fibrillation: a meta-analysis of randomized-controlled trials. Int J Rehabil Res. 2017;40(3):193–201. - PubMed
-
- Garnvik L.E., Malmo V., Janszky I., Wisloff U., Loennechen J.P., Nes B.M. Physical activity modifies the risk of atrial fibrillation in obese individuals: the HUNT3 study. Eur J Prev Cardiol. 2018;25(15):1646–1652. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous